Compare Funko Inc (FNKO) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Illumina, Inc. — how do they compare? Funko Inc trades at $6.49 (market cap $363.97M), while Illumina, Inc. trades at $265.01 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 109.8× Funko Inc's market cap, and Illumina, Inc. is more actively traded (3,169,503 versus 1,422,651). Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Illumina, Inc. for 83 Days on average.
| FNKO | ILMN | |
|---|---|---|
Market Cap | $363.97M | $39.95B |
Volume | 1,422,651 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $293.69 |
52-Week Low | $2.81 | $91.00 |
Typical Hold Time | 33 Days | 83 Days |
Enterprise Value | $584.62M | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.31, up 3.27% with strong technical momentum and bullish moving average signals. The stock shows improving fundamentals with recent earnings beats and raised EBITDA guidance, though profitability remains challenged with negative net margins. Analyst consensus leans Hold with a $7.58 price target, representing 20% upside potential from current levels.
The outlook suggests cautious optimism as operational improvements and debt reduction progress, but investors face risks from inconsistent profitability and competitive pressures in the collectibles market. The stock's attractive valuation multiples and recent management changes provide potential catalysts for recovery.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
